Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.…
Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks
Avalo Therapeutics (NASDAQ: AVTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 6.760 USD on 20 November 2026, down 55.1% over 52 weeks. Its 52-week range is 6.530 USD to 24.27 USD: the price is 72.1% below the high and 3.5% above the low.
Its market capitalisation is 390.88M USD.
Avalo Therapeutics reports return on equity of -94.2%.
It holds more cash than debt, a net cash position of 392.81M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.